Quantitative prediction of antitarget interaction profiles for chemical compounds

Chemical Research in Toxicology

Volumn 25, Issue 11, 2012, Pages 2378-2385

  Zakharov, Alexey V ^a,b   Lagunin, Alexey A ^b   Filimonov, Dmitry A ^b   Poroikov, Vladimir V ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMINEPTINE; ANDROGEN RECEPTOR ANTAGONIST; ANTIESTROGEN; ASTEMIZOLE; BROMFENAC; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CERIVASTATIN; CHLORMEZANONE; DELTA OPIATE RECEPTOR ANTAGONIST; DOPAMINE RECEPTOR BLOCKING AGENT; FENFLURAMINE; FLOSEQUINAN; GLAFENINE; GREPAFLOXACIN; IBUPROFEN; KAPPA OPIATE RECEPTOR ANTAGONIST; MIBEFRADIL; MONOAMINE OXIDASE A INHIBITOR; MU OPIATE RECEPTOR ANTAGONIST; ROFECOXIB; SEROTONIN 1B ANTAGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; TROGLITAZONE; UNINDEXED DRUG; XIMELAGATRAN;

ACCURACY; ARTICLE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; INFORMATION SERVICE; PROTEIN TARGETING; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALGORITHMS; DATABASES, PROTEIN; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANIC CHEMICALS; PROTEINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE;

EID: 84869412244     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx300247r     Document Type: Article

References (26)

1. European Federation of Pharmaceutical Industries and Associations. ((2010) in The Pharmaceutical Industry in Figures, EFPIA, Brussels, Belgium.
2. Czerepak, E. and Ryser, S. (2008) Drug approvals and failures: implications for alliances Nature Rev. Drug Discovery 7, 197-198
3. Schuster, D., Laggner, C., and Langer, T. (2008) Why Drugs Fail: A Study on Side Effects in New Chemical Entities, in Antitargets (Vaz, R. J. and Klabunde, T., Eds.) pp 3-22, Wiley-VCH, Wienheim, Germany.
4. Larrey, D., Berson, A., Habersetzer, F., Tinel, M., Castot, A., Babany, G., Letteron, P., Freneaux, E., Loeper, J., Dansette, P., and Pessyre, D. (1989) Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant Hepatology 10, 168-173
5. FDA Duract Volunterily Withdrawn, http://www.fda.gov/downloads/Safety/ MedWatch/SafetyInformation/UCM189811.zip (accessed Dec 14, 2010).
6. FDA (2004) FDA Issues Public Health Advisory on Vioxx as Its Manufacturer Voluntary Withdraws the Product, in FDA News, FDA, Silver Spring, MD.
7. Dukes, M. N. G. and Aronson, J. K. (2006) In Meyler's Side Effects of Drugs, 14 th ed., An Encyclopedia of Adverse Reactions and Interactions, Elsevier, Atlanta, GA.
8. Klabunde, T. and Evers, A. (2005) GPCR anti-target modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects ChemBioChem 6, 876-889
9. Chen, Y. Z. and Ung, C. Y. (2001) Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach J. Mol. Graphics Modell. 20, 199-218
10. Fanelli, F., Menziani, M., Carotti, A., Benedetti, P. A., and Benedetti, De. (1994) Theoretical quantitative structure-activity relationship analysis on three dimensional models of ligand-m1 muscarinic receptor complexes Bioorg. Med. Chem. 2, 195-211
11. Lopez-Rodriguez, M., Rosado, M., Benhamu, B., Morcillo, M., Fernandez, E., and Schaper, K. (1997) Synthesis and structure-activity relationships of a new model of arylpiperazines. 2. Three dimensional quantitative structure-activity relationships of new hydantoin-phenylpiperazine derivatives with affinity for 5-HT1A and alpha1 receptors. A comparison of CoMFA models J. Med. Chem. 40, 1648-1656
12. Vistoli, G., Pedretti, A., Villa, L., and Tesla, B. (2005) Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses J. Med. Chem. 48, 4947-4952
13. Hegymegi-Barakonyi, B., Eros, D., Szántai-Kis, C., Breza, N., Bánhegyi, P., Szabó, G., Várkondi, E., Peták, I., Orfi, L., and Kéri., G. (2009) Tyrosine kinase inhibitors-small molecular weight compounds inhibiting EGFR Curr. Opin. Mol. Ther. 11 (3) 308-321
14. Matthews, E. and Frid, A. (2010) Prediction of drug-related cardiac adverse effects in humans. A: Creation of a database of effects and identification of factors affecting their occurrence Regul. Toxicol. Pharmacol. 56 (3) 247-275
15. Filimonov, D. A., Zakharov, A. V., Lagunin, A. A., and Poroikov, V. V. (2009) QNA based 'Star Track' QSAR approach SAR and QSAR Environ. Res. 20 (7-8) 679-709
16. Lagunin, A. A., Zakharov, A. V., Filimonov, D. A., and Poroikov, V. V. (2011) QSAR modelling of rat acute toxicity on the basis of PASS prediction Mol. Inf. 30 (2-3) 241-250
17. Lagunin, A. A., Zakharov, A. V., Filimonov, D. A., and Poroikov, V. V. (2007) A new approach to QSAR modelling of acute toxicity SAR QSAR Environ. Res. 18 (3-4) 285-298
18. Sadym, A., Lagunin, A., Filimonov, D., and Poroikov, V. (2003) Prediction of biological activity spectra via Internet SAR QSAR Env. Res. 14, 339-347
19. Maurer, I. and Volz, H. (2001) Cell-mediated side effects of psychopharmacological treatment Arzneimittelforschung 51 (10) 785-792
20. Rang, H. P., Dale, M. M., and Ritter, J. M. (1999) In Pharmacology, 4 th ed., Churchill Livingstone, Philadelphia, PA.
21. Gutstein, H.B. and Akil, H. (2006) In Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton, L. L., Lazo, J. S., and Parker, K. L., Eds.) 11 th ed., pp 547-590, The McGraw-Hill Companies, New York.
22. Maus, M., Glowinski, J., and Premont, J. (2002) GABA is toxic for mouse striatal neurones through a transporter-mediated process: GABA toxicity in striatal neurones J. Neurochem. 82 (4) 763-773
23. Lei, B., Xi, L., Li, J., Liu, H., and Yao, X. (2009) Global, local and novel consensus quantitative structure-activity relationship studies of 4-(phenylaminomethylene) isoquinoline-1,3 (2H, 4H)-diones as potent inhibitors of the cyclin-dependent kinase 4 Anal. Chim. Acta 644 (1-2) 17-24
24. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many drug targets are there? Nat. Rev. Drug Discovery 5, 993-996
25. ChemAxon Ltd, MarvinSketch 5.4.1.1, http://www.chemaxon.com/marvin/help/ index.html (accessed May 10, 2011).
26. FDA. ((1992) In Omniflox Recalled-Antibiotic, FDA Consumer, U.S. Government Printing Office, Washington, DC.